Nov 16, 2009 - Proteo, Inc.and its wholly-owned subsidiary Proteo Biotech AG announced today:
The Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) has issued a recommendation granting orphan drug status to Proteo's drug candidate Elafin for the treatment of esophagus carcinoma.
The details can be read here.
No comments:
Post a Comment